Loading...
XLONAGY
Market cap414mUSD
Jan 03, Last price  
7.00GBP
1D
2.94%
1Q
44.33%
Jan 2017
-66.47%
Name

Allergy Therapeutics PLC

Chart & Performance

D1W1MN
XLON:AGY chart
P/E
—
P/S
604.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.81%
Rev. gr., 5y
-5.62%
Revenues
55m
-7.36%
20,606,00023,558,00025,742,00031,022,00037,757,00040,750,00041,552,00041,280,00039,279,00041,955,00043,230,00048,509,00064,138,00068,346,00073,717,00078,204,00084,331,00072,768,00059,587,00055,199,000
Net income
-40m
L-6.63%
-2,191,000-6,173,000-23,256,000-20,297,000-11,764,000586,000-2,662,000823,000536,000741,000108,000-13,072,000-2,481,000-7,533,0003,467,0007,058,0002,886,000-13,776,000-43,071,000-40,216,000
CFO
-32m
L+3.95%
-57,000-8,103,000-18,877,000-19,322,000-440,0001,702,000-2,027,0002,880,0002,432,0002,173,0003,123,000-11,839,000178,000-3,802,0005,600,00012,276,0008,516,000-14,111,000-30,916,000-32,138,000
Earnings
Mar 25, 2025

Profile

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
URL
https://www.allergytherapeutics.com/
IPO date
Oct 11, 2004
Employees
622
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
55,199
-7.36%
59,587
-18.11%
72,768
-13.71%
Cost of revenue
90,743
95,901
86,305
Unusual Expense (Income)
NOPBT
(35,544)
(36,314)
(13,537)
NOPBT Margin
Operating Taxes
1,050
449
379
Tax Rate
NOPAT
(36,594)
(36,763)
(13,916)
Net income
(40,216)
-6.63%
(43,071)
212.65%
(13,776)
-577.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,417
6,489
3
BB yield
-1.23%
-42.44%
0.00%
Debt
Debt current
2,116
1,803
2,268
Long-term debt
36,760
34,186
8,261
Deferred revenue
7,747
6,764
Other long-term liabilities
11,701
11,498
8,463
Net debt
25,961
21,144
(9,986)
Cash flow
Cash from operating activities
(32,138)
(30,916)
(14,111)
CAPEX
(3,401)
(4,669)
(3,056)
Cash from investing activities
(1,199)
(4,669)
(3,056)
Cash from financing activities
31,431
29,913
(2,638)
FCF
(37,329)
(32,588)
(27,146)
Balance
Cash
12,915
14,845
20,515
Long term investments
Excess cash
10,155
11,866
16,877
Stockholders' equity
(192,840)
(116,964)
(74,811)
Invested Capital
239,238
162,074
127,301
ROIC
ROCE
EV
Common stock shares outstanding
3,743,332
1,456,288
1,396,840
Price
0.05
399.05%
0.01
-94.94%
0.21
-17.00%
Market cap
196,151
1,182.78%
15,291
-94.72%
289,844
-21.13%
EV
222,112
36,435
279,858
EBITDA
(31,225)
(32,090)
(9,371)
EV/EBITDA
Interest
4,107
2,158
541
Interest/NOPBT